SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins stronger-than-expected quarterly results, upbeat forward guidance, and expanded share-repurchase authorization drove a sharp rebound after a steep decline. Traders largely celebrated the results and speculated about a short squeeze, while others warned the rally could fade and questioned the pace of future growth and rising AI costs.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns sharp decline is being discussed as part of a broader semiconductor and AI-stock selloff, with traders speculating that election-related data-center restrictions or delays could weaken future AI infrastructure demand. Bulls call the move an overreaction given Microns strong results and memory demand, while bears point to cyclical supply risks and question whether the recent boom can last.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snaps quarterly results sparked a selloff as daily active-user growth fell short of expectations and advertising growth remained soft, with traders especially concerned about North American user trends. The reaction is disputed: bears focus on weaker audience metrics, while bulls point to improved profitability and the stronger fourth-quarter outlook.

Redwire Corp. engages in the development and provision of space and defense technologies and mission-critical solutions for government, commercial, and civil customers. Its offerings include spacecraft platforms, space infrastructure, avionics, sensors and payloads, power generation systems, radio frequency systems, microgravity research and manufacturing technologies, autonomous systems, optical sensors, and digital engineering solutions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwires Q3 results are driving attention, with a revenue shortfall weighing on shares while improved margins, record backlog and reaffirmed guidance fuel a more optimistic view. Traders are divided over whether the miss signals execution risk or reflects revenue timing while the business improves operationally.

Sezzle, Inc. engages in the operation of a digital payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie G. Youakim, Killian Brackey and Paul V. Paradis on January 4, 2016 and is headquartered in Minneapolis, MN.

Sezzle Inc.

Sezzles strong quarterly results and another increase to its 2026 outlook, alongside an upbeat preliminary 2027 outlook, are driving attention. Bulls are celebrating the growth and speculating about short-covering, while some traders question whether projected growth is slowing enough to temper the rally.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is under pressure as Democratic gains fuel trader concerns about tighter AI regulation and data-center permitting delays, despite strength in other mega-cap tech stocks. The community is split over whether this threatens chip demand or merely redirects and delays data-center investment, with some viewing the selloff as a buying opportunity and others warning of slower AI spending.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomms quarterly results and outlook are driving attention: a modest earnings beat was overshadowed by falling handset sales and warnings that memory and supplier costs will pressure margins, contributing to a sharp after-hours selloff. Traders are split on whether growth in automotive, IoT and data-center chips can offset smartphone weakness.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Traders link SNDKs sharp selloff with fears that election results and local resistance could slow data-center expansion, putting AI-driven memory demand at risk; broader concerns about memorys cyclical pricing and peak margins add to the pressure. The community is divided: bears see a lasting demand and valuation problem, while bulls argue the policy fears are overstated and point to strong results, constrained memory supply, buybacks, and the planned stock split.

Coherent Corp. engages in the development, refinement, manufacturing, and marketing of engineered materials, opto-electronic components and devices, and lasers for use in the industrial, communications, electronics, and instrumentation markets. It operates through the following segments: Networking, Materials, and Lasers. The Networking segment leverages compound semiconductor technology platforms and deep knowledge of end-user applications. The Materials segment markets engineered materials and optoelectronic devices. The Lasers segment serves industrial customers in semiconductor capital equipment, display capital equipment, precision manufacturing, and aerospace and defense, as well as instrumentation customers in life sciences and scientific research. The company was founded by Carl J. Johnson in 1971 and is headquartered in Saxonburg, PA.

Coherent Corp

Coherents strong quarterly results and raised outlook, driven by AI data-center optical demand, are the main focus, but the shares are selling off despite the beat. Traders are split between viewing the pullback as broad AI-sector de-risking and worrying that data-center spending concerns could outweigh the companys growth outlook.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCrysts quarterly earnings beat and higher full-year revenue outlook are driving discussion, but the stocks weak reaction has frustrated holders. Traders debate whether the raised total outlook signals stronger growth or overstates momentum, since ORLADEYO guidance was unchanged and some of the reported revenue boost came from other sources; bulls cite improving operations while skeptics focus on competition, debt and the wait for pipeline progress.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Novo CEO Brushes Off Post-Midterm Drug-Pricing Fears, Says ‘Our World’ Won’t Change Dramatically – NVO Stock Gains Pre-Market

Novo Nordisks quarterly sales beat and raised full-year outlook, supported by strong Wegovy pill and broader GLP-1 demand, are driving attention. Bulls see signs of a recovery, while skeptics point to profit pressure, diabetes weakness, Lillys competition and lingering doubts about management and execution.

The move appears tied to Novos stronger-than-expected Q3 sales, including DKK 5.4 billion in Wegovy pill sales, and its improved 2026 outlook: adjusted sales and operating-profit growth are now forecast at -2% to +2%, versus a prior range of -6% to flat. The company attributed the outlook improvement to stronger expectations for GLP-1 drug sales.

NVO Q3 Earnings Beat Estimates on Wegovy Pill Growth, Outlook Raised

Novo beats Q3 earnings and revenue estimates as Wegovy pill sales surge, driving a higher 2026 outlook despite diabetes weakness and pricing pressures.

AMGN Stock Down Despite Q3 Earnings & Sales Beat, Raised Guidance

Amgen shares fall despite Q3 earnings and revenue beats. Steep declines in Prolia and Xgeva offset strong growth across key drug portfolios and raised 2026 guidance.

Equity

CEO Mike Doustdar told CNBC that while the company has experienced weak growth in the past due to pricing, volumes have grown ‘phenomenally.’


Novo Nordisk raises 2026 outlook as Q3 obesity sales jump 22% -

Novo Nordisk raises 2026 outlook as Q3 obesity sales jump 22%??Yahoo Finance...

Novo Nordisk Q3 Adj. Operating Profit Increases, Obesity Sales Up 22%; Raises 2026 Outlook

(RTTNews) - Novo Nordisk A/S (NVO, NOVOB.CO, NOV.DE) reported third quarter net profit of 16.74 billion Danish kroner, a decline of 16% year-over-year. Earnings per share/ ADR was 3.79 kroner, down 16%. Adjusted net profit was 25.60 billion kroner, down 12% from last year. Adjust...

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets 

ASH will release regular meeting abstracts on Wednesday, followed by late-breaking abstracts on Dec.7.

3 Dirt Cheap Dividend Stocks to Buy in November 2026

Key PointsAT&T, Novo Nordisk, and Vici Properties have struggled this year but remain high-quality investments...

Peptide Therapies Are Changing the Future of Medicine — And the Market Could Reach $335 Billion

Growing Demand for Next-Generation Therapies Is Putting Peptide Innovation at the Center of Healthcare’s Biggest Growth Markets   New York, NY –November 3, 2026 – Peptide-based treatments are attracting growing attention from major pharmaceutical companies as researchers push into new ways to treat diabetes, obesity, cancer, metabolic disorders and other serious diseases. The opportunity is […]
The post Peptide Therapies Are Changing the Future of Medicine — And the Market Could Reach $335 Billion appeared first on Financial News Media.

LLY Stock Up Almost 10% After a Robust Q3: Time to Buy, Sell or Hold?

Lilly's stock rose 9.6% after strong Q3 results. Can its obesity pipeline and expanding drug portfolio sustain growth amid rising competition & pricing pressure?

Will These 5 Drug Bigwigs Surpass Q3 Earnings Forecasts?

AMGN, PFE, MRNA, NVO and VTRS are set to report this week as recent beats and key drug demand set up a pivotal Q3 earnings test for pharma giants.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>Novo reported 4% sales growth in CER in Q3 at DKK79.20 billion, beating Wall Street’s estimates of DKK73.40 billion, according to Fiscal.ai.</li><li>The company expects adjusted sales and operating profit growth between -2% and +2% at CER in FY2026.</li><li>Novo attributed the improved outlook to stronger expectations for GLP-1 drug sales.</li></ul>Novo Nordisk (NVO) CEO Mike Doustdar downplayed concerns about tougher U.S. drug-pricing regulations following the Democrats’ midterm election victory, saying he does not expect major changes to the company’s business.Speaking to CNBC on Wednesday, Doustdar added that Novo has worked with lawmakers from both parties to make drug prices more affordable. He added that while the company has experienced weak growth in the past due to pricing, volumes have grown “phenomenally.”“The volumes have been growing phenomenally. That’s actually when you take the pill even out of this equation and look at the injectable, volumes are growing incredibly healthy. Now, the reason it grows is because we made our products more affordable,” Doustdar said.“So that’s a fair balance, and we will work with both Republicans, as well as Democrats, on that agenda. So, I don't foresee that our world will change dramatically,” he added.<h2 class="st-heading-2">Novo’s Pricing In Focus</h2>His comments come amid concerns that Democrats could push for further drug-price reductions following victory in the midterm elections.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk-us.com/media/press-releases/novo-nordisk-lowers-wegovy-ozempic-list-price.html">plans</a> to reduce U.S. list prices for Wegovy and Ozempic to $675 per month starting January 2027, representing cuts of about 50% and 35%, respectively.<a class="mention" data-mention="$NVO" data-symbol-id="NVO" href="https://stocktwits.com/symbol/NVO" target="_blank">NVO shares</a> jumped 5% in premarket trading on Wednesday, putting the stock on track for its biggest single-day gain since June, after the Danish drugmaker reported stronger-than-expected third-quarter topline and raised its full-year outlook.<h2 class="st-heading-2">Novo Raises FY2026 Earnings Outlook</h2>Novo reported 4% sales growth in constant exchange rates (CER) in Q3 at DKK79.20 billion ($11.93 billion), beating Wall Street’s estimates of DKK73.40 billion, according to Fiscal.ai. Operating profit fell 9% at CER, due to DKK8.7 billion in non-cash impairment charges.According to CNBC, sales of its Wegovy pill, launched earlier this year, came in at DKK 5.4 billion, while sales of injectable Wegovy and Ozempic were DKK20.4 billion and DKK29.7 billion.The company now expects adjusted sales and operating profit growth between -2% and +2% at CER in full year 2026, compared with its previous forecast of a 6% decline to flat growth. Novo attributed the improved outlook to stronger expectations for GLP-1 drug sales.<h2 class="st-heading-2">Retail Bulls Eye $100</h2>Retail sentiment surrounding NVO on Stocktwits turned ‘bullish’ from ‘neutral’ over the past 24 hours, amid ‘high’ message volumes. NVO was also among the top trending tickers at the time of writing.<img src="https://news.stocktwits-cdn.com/NVO_60d8e994ab.png" alt="NVO.png">One user expects the stock to climb to $100 based on its improved outlook. NVO is currently trading at around $41.<stembedurl>https://stocktwits.com/Pseudominds/message/668104293</stembedurl>NVO shares are down 18% so far in 2026, significantly underperforming rival Eli Lilly’s 30% gains.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Novo Nordisk logo is seen with tablets, capsules, and syringes in this photo illustration in Brussels, Belgium, on August 9, 2025. 

CEO Mike Doustdar told CNBC that while the company has experienced weak growth in the past due to pricing, volumes have grown ‘phenomenally.’

Current Price	$42.18
Prev Close	$40.19
Open	$42.45
Dividend Yield	2.53%
50-Day Moving Average	$40.97
Beta	0.82
Avg. Volume	10.76M
PE Ratio	9.81

52-Week High	$64.16
52-Week Low	$35.12
Market Capitalization	$134.47B
EPS (Annual)	$3.49
Price to Book	5.25
Revenue Per Employee	$679,358.45

Feed

News

Sentiment

Earnings

Fundamentals

Info

NVO Fundamentals